Return to AIDS/HIV Alert Section
New HIV/AIDS research from J. Liu and co-researchers described
December 31st, 2007
2007 DEC 31 -- According to recent research from Fuzhou, People's Republic of China, "The database of genotypic drug resistance mutations in HIV-1 subtype B circulating in developed industrial countries has been well established; however, little is known regarding the prevalence of genotypic resistance patterns in patients harboring non-subtype-B HIV-1 variants in most Asian countries. To characterize the polymorphisms and emergence of drug-resistance mutations, resistance to antiretroviral drugs in naive and pretreated patients infected with HIV-1 CRF01_AE isolates in Fujian province, China." "HIV-1 pol amplicons from 52 pre- and 14 post-treatment samples were obtained by reverse transcription-polymerase chain reaction (RT-PCR) and sequencing. All of the 14 antiretroviral-treated patients were under a fixed regimen of stavudine (d4T), lamivudine (3TC) and nevirapine (NVP), and they had been on treatment for a mean of 6 months (SD, 4 months). The sequence data were analyzed using the Bioedit software, and the data regarding drug resistance mutations were obtained using the Stanford (http://hivdb.standford.edu). In comparison with the consensus sequence of B strains, the most common protease polymorphisms in HIV-1 CRF01_AE strains prevailing in Fujian Province, China, were I13V (76.9%), E35D (76.9%), M36I (100%), R41K (98.1%), H69K (90.4%), and L89M (96.2%). Protease mutations between CRF01_AE strains and B' variants prevailing in China were observed. The proportion of substitutions L63P, A71T/V, V77I and I93L in subtype B' sequences was considerably higher than in CRF01_AE viruses, while the proportion of L10I, M36I and K20R/I substitutions in subtype B' sequences was relatively lower than in CRF01_AE strains. A high level of resistance to nucleoside reverse transcriptase inhibitors (NRTIs) (28.6%, 4/14) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) (35.7%, 5/14) was found in treatment-experienced patients. High-level resistance to nevirapine (NVP) and lamivudine (3TC) was found in the stavudine/lamivudine/nevirapine (d4T/3TC/NVP) treatment regimen. The overall drug resistance rate was 42.9% (6/14), the resistance rates to two and to all three drugs under treatment were 14.3% (2/14) and 7.1% (1/14), respectively. This study is the first report on polymorphisms and emergence of drug-resistance mutations in HIV-1 subtype CRF01_AE prevailing in China," wrote J. Liu and colleagues. The researchers concluded: "These findings provide useful information on global HIV genetic variability and non-B drug resistance." Liu and colleagues published their study in Archives of Virology (Polymorphisms and drug resistance analysis of HIV-1CRF01_AE strains circulating in Fujian Province, China. Archives of Virology, 2007;152(10):1799-1805). For additional information, contact Y. Yan, Center Diseases Control & Prevention, Fuzhou 350001, Fujian, People's Republic of China. Publisher contact information for the journal Archives of Virology is: Springer Wien, Sachsenplatz 4-6, PO Box 89, A-1201 Wien, Austria. Keywords: People's Republic of China, Fuzhou, HIV/AIDS, AIDS, Acquired Immunodeficiency Syndrome, Antivirals, Biotechnology, Diagnosis, Diagnostics, Drug Development, Drug Resistance, Drugs, Enzyme Research, Enzymology, Gene Therapy, HIV, Human Immunodeficiency Virus, Lamivudine, Nevirapine, Nonnucleoside Reverse Transcriptase Inhibitor, Nucleoside Reverse Transcriptase Inhibitor, Pharmaceuticals, Polymerase, Protease, Stavudine, Treatment, Virology. This article was prepared by Anti-Infectives Week editors from staff and other reports. Copyright 2007, Anti-Infectives Week via NewsRx.com.
Return to AIDS/HIV Alert Section
|
